Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445468 | 0.84 | ELANE (0.47) | MAPTHDAC8ELANEALDH1A1KDM4E | |
| SCHEMBL12083366 | 0.80 | KDM4E (0.54) | MAPTALDH1A1KDM4EMAPK1KMT2A | |
| SCHEMBL16722809 | 0.79 | ALDH1A1 (0.47) | MAPTELANEALDH1A1KDM4EMAPK1 | |
| SCHEMBL14215786 | 0.78 | MAPT (0.56) | MAPTHDAC8ALDH1A1KDM4EMAPK1 | |
| SCHEMBL26054307 | 0.78 | NPC1 (0.45) | ALDH1A1KMT2A | |
| SCHEMBL5058742 | 0.77 | ALDH1A1 (0.45) | MAPTHDAC8ELANEALDH1A1KDM4E | |
| SCHEMBL15214044 | 0.77 | GABRA1 (0.45) | MAPTELANEALDH1A1KMT2ACA1 | |
| SCHEMBL5079740 | 0.76 | PDK2 (0.42) | MAPTELANEALDH1A1KDM4EMAPK1 | |
| SCHEMBL7949878 | 0.76 | HPGD (0.47) | ELANEALDH1A1KDM4EKMT2ATP53 | |
| SCHEMBL5847579 | 0.76 | ALDH1A1 (0.64) | MAPTHDAC8ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995061-B2 | SPAK kinase inhibitors as neuroprotective agents | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-05-04 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-5541045-A | MAGENTA COUPLERS FOR PHOTOGRAPHIC FILMS IN SILVER HALIDE EMULSIONS AND MULTILAYER ELEMENTS | FUJI PHOTO FILM CO., LTD. (JP) | 1996-07-30 | — | — | US | disclosed |
| US-5538842-A | COLORFAST PHOTOGRAPHIC FILM | FUJI PHOTO FILM CO., LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | MAPT 4286/4885HDAC8 911/4885ELANE 4386/4885 |
| US-10995061-B2 | SPAK kinase inhibitors as neuroprotective agents | SBK1, DAPK2, SPAST | MAPT 833/4885HDAC8 367/4885ELANE 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.